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Abstract
Background: Although lung cancer is among the few malignancies for which we know the primary
etiological agent (i.e., cigarette smoke), a precise understanding of the temporal sequence of events that
drive tumor progression remains elusive. In addition to finding that cigarette smoke (CS) impacts the
functioning of key pathways with significant roles in redox homeostasis, xenobiotic detoxification, cell
cycle control, and endoplasmic reticulum (ER) functioning, our data highlighted a defensive role for the
unfolded protein response (UPR) program. The UPR promotes cell survival by reducing the accumulation
of aberrantly folded proteins through translation arrest, production of chaperone proteins, and increased
degradation. Importance of the UPR in maintaining tissue health is evidenced by the fact that a chronic
increase in defective protein structures plays a pathogenic role in diabetes, cardiovascular disease,
Alzheimer's and Parkinson's syndromes, and cancer.
Methods: Gene and protein expression changes in CS exposed human cell cultures were monitored by
high-density microarrays and Western blot analysis. Tissue arrays containing samples from 110 lung
cancers were probed with antibodies to proteins of interest using immunohistochemistry.
Results: We show that: 1) CS induces ER stress and activates components of the UPR; 2) reactive species
in CS that promote oxidative stress are primarily responsible for UPR activation; 3) CS exposure results
in increased expression of several genes with significant roles in attenuating oxidative stress; and 4) several
major UPR regulators are increased either in expression (i.e., BiP and eIF2α) or phosphorylation (i.e.,
phospho-eIF2α) in a majority of human lung cancers.
Conclusion: These data indicate that chronic ER stress and recruitment of one or more UPR effector
arms upon exposure to CS may play a pivotal role in the etiology or progression of lung cancers, and that
phospho-eIF2α and BiP may have diagnostic and/or therapeutic potential. Furthermore, we speculate that
upregulation of UPR regulators (in particular BiP) may provide a pro-survival advantage by increasing
resistance to cytotoxic stresses such as hypoxia and chemotherapeutic drugs, and that UPR induction is a
potential mechanism that could be attenuated or reversed resulting in a more efficacious treatment
strategy for lung cancer.
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Background
The long lag time between initiation of cigarette smoking
and cancer induction (estimated at 25 to 50 pack-years)
[1,2] raises several fundamental questions concerning the
eventual induction of tobacco-induced diseases for which
there is little information: e.g., how does the lung adapt to
the chronic assault of many decades of cigarette smoke
(CS) exposure, what are the biological sequelae that occur
in response to this adaptation and the continuous disrup-
tion of normal cellular homeostasis in the lung, and is this
adaption a help or hindrance to lung cancer develop-
ment? Our working hypothesis is that a) tobacco-induced
lung cancer is a complex process in which numerous pro-
survival cellular systems have important contributory
functions that both augment and modify the central role
played by tobacco carcinogens and reactive oxygen/nitro-
gen species, and b) CS temporally shapes the course of
lung carcinogenesis through chronic activation, and even-
tual dysregulation, of normal cellular defense mecha-
nisms. In our published [3-6] and unpublished studies
using high-density oligonucleotide arrays and other tech-
niques to define relevant CS-induced alterations in gene/
protein expression and function in lung cells, we have
attempted to place the impacted genes into biological
context by developing a plausible mechanistic model
relating disruption of specific cellular circuits to pulmo-
nary disease. Thus, in addition to revealing that CS affects
the functioning of several important molecular pathways
(e.g., redox homeostasis, detoxification of xenobiotics
and cell cycle control), these data highlighted a potential
role for the unfolded protein response (UPR) program.
Successful maturation of secretory and membrane pro-
teins in the endoplasmic reticulum (ER) involves proper
folding, assembly, and post-translational modification
[7]. A wide range of stressful situations (e.g., hypoxia, viral
infection, alterations in glycosylation status, disruption of
calcium homeostasis, and oxidative stress), can disrupt
this maturation process, resulting in the accumulation of
unfolded or misfolded proteins and causing ER stress [8].
The ER attempts to attenuate this stress by activating an
adaptive set of stress response signaling pathways termed
the Unfolded Protein Response (UPR) [8,9]. The primary
function of the UPR is to reduce the accumulation of aber-
rantly folded proteins in the ER and promote cell survival
through a transient decrease in protein translation cou-
pled with increases in the ER's capacity to refold and
degrade these proteins[10,11]. If this pro-survival
response fails to restore homeostatic equilibrium in the
ER, a secondary response, triggered in part by the same ER
stress sensors that activate the UPR program, promotes
apoptosis and cell death. The importance of a properly
functioning ER in maintaining cellular and tissue health is
clear from the mounting evidence that a chronic increase
in defective protein structures coupled with dysregulation
within the ER can play a pathogenic role in diabetes, car-
diovascular disease, Alzheimer's and Parkinson's syn-
dromes, and cancer [12-14].
An accumulation of misfolded proteins induces the disso-
ciation of the ER-resident master chaperone regulator,
BiP/GRP78 (Binding Immunoglobulin Protein/Glucose
Response Protein 78), from three ER transmembrane sen-
sor proteins: ATF6 (Activation of Transcription Factor 6),
Ire1 (Inositol Requiring Enzyme 1α), and PERK (Protein
Kinase R-like ER Kinase) resulting in activation of their
respective molecular functions [15,16]. A second mecha-
nism driving activation of these sensor proteins may also
involve binding of unfolded protein domains to a pep-
tide-binding groove in both IRE1 and PERK, and possibly
ATF6 [17]. Upon experiencing stress the 90 kDa ATF6 pro-
tein translocates from the ER to the Golgi where it is pro-
teolytically processed to a functional 50 kDa transcription
factor that binds to specific ER stress elements and directs
the synthesis of chaperone proteins that mitigate protein
misfolding through various mechanisms [18,19]. IRE1
has, in addition to a kinase domain, an endoribonuclease
domain that splices an intron from the XBP1 (X-box Bind-
ing Protein) mRNA resulting in the synthesis of a tran-
scriptional activator that modulates expression of a
number of genes involved in ER homeostasis, DNA dam-
age repair, and redox homeostasis [20-22]. As well as
being a transcriptional activator, IRE1 can also mediate
the rapid degradation of a specific subset of mRNAs that
would interfere with the coordinated reestablishment of
normal ER function [23]. In contrast to these pro-survival
functions, IRE-1 can also directly regulate both pro- and
anti-apoptotic circuits via activation of the stress kinase
JNK-1 and mitogen-activated protein kinase ERK-1 [24-
26]. Unlike the transcriptionally active ATF6 and XBP1
proteins, PERK, upon release from BiP/GRP78, undergoes
autophosphorylation and activation of a kinase function
that phosphorylates the alpha subunit of eIF2 (eukaryotic
translation initiation factor 2) and a transient repression
of global protein synthesis. This temporary decrease in
newly synthesized proteins entering the ER provides time
to reestablish homeostatic equilibrium and resume nor-
mal protein maturation [27,28].
Since habitual U.S. smokers consume an average of 16.6
cigarettes/day [29], and probably inhale somewhere
between 120–180 puffs/day of a complex mixture of reac-
tive gases and particulate matter composed of a wide
range of entities (e.g., carcinogens and reactive oxygen/
nitrogen radicals) that cause both immediate and delayed
damage to proteins, lipids, and nucleic acids, it is likely
that the lung cell is protected by multiple pro-survival
mechanisms, including the UPR. Two recent studies have
begun to amass data showing that CS induces elements of
the UPR program in lung cells [30,31]. These reports spec-BMC Cancer 2008, 8:229 http://www.biomedcentral.com/1471-2407/8/229
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ulate that elements of the UPR signaling pathway are rel-
evant to human smoking-related diseases. However, there
is minimal data detailing the impact of CS on all three
UPR effector arms in both normal and malignant lung
cells. Moreover, there is inconclusive evidence of UPR
activation in human lung cancers. Thus, we were inter-
ested in determining the impact of CS on the UPR path-
way in NHBE lung cells in vitro, and assessing the status
of UPR activation in vivo in human lung cancers. We
report here that CS exposure induces ER stress and triggers
the UPR in both normal and malignant human lung cells.
Of greater clinical relevance, however, is that an immuno-
histochemical analysis of a human lung tumor tissue array
containing 110 lung cancer specimens and 10 normal
lung tissue controls from a total of 120 patients showed a
statistically significant increase in the total levels of phos-
pho-eIF2α, BiP, and eIF2α in lung cancers compared to
non-malignant lung cells.
These data implicate dysregulation of the UPR pathway in
the pathogenesis of human lung cancers and indicate that
phospho-eIF2α and BiP (and possibly eIF2α), may have
diagnostic and/or therapeutic potential [32,33]. Further-
more, the activation of the UPR program via eIF2α phos-
phorylation indicates a previously unknown pathogenic
effect of CS and suggests that chronic induction of one or
more protein effectors of the UPR pathway may play an
etiological role in lung cancer. Finally, the upregulation of
several UPR regulators (in particular) in lung cancers may
provide a pro-survival advantage by increasing cellular
resistance to various cytotoxic stresses such as hypoxia,
chemotherapeutic drugs, and immune attack [34-38],
especially in tumor cells that have one or more pro-apop-
totic pathways disabled, which is a common feature of
lung neoplasms [39].
Methods
Cell Culture and Smoke Treatment
A549 cells were purchased from American Type Culture
Collection (ATCC no. CCL-185, Manassas, VA) and were
cultured in Ham's F12K medium with 2 mM L-glutamine
adjusted to contain 1.5 g/L sodium bicarbonate (Gibco/
Invitrogen, Carlsbad, CA) and supplemented with 10%
fetal bovine serum (ATCC). NHBE cells from nonsmok-
ing, nondiabetic donors were purchased from Cambrex
Corporation (Walkersville, MD). Cells were cultured in
complete Bronchial Epithelial Cell Growth Medium, pre-
pared by supplementing Bronchial Epithelial Basal
Medium with retinoic acid, epidermal growth factor,
epinephrine, transferrin, T3, insulin, hydrocortisone, anti-
microbial agents and bovine pituitary extract by addition
of SingleQuots,™ (Cambrex Corporation). All cell cultures
were treated before their sixth passage. All incubations
were at 37°C in a humidified atmosphere of 5% CO2 in
air. CS treatment was performed as follows: cells were
seeded into 35 mm Petri dishes (Fisher Scientific, Falcon
#35-3001, Pittsburg, PA) at a density of 105 cells/dish and
were typically at 70% confluency at the time of exposure
to CS. At least three replicate dishes were treated for each
condition, and each replicate was analyzed using a sepa-
rate microarray (i.e., the RNA from the dishes was not
pooled). The cell culture medium was replaced with 37°C
Dulbecco's PBS (D-PBS) containing calcium and magne-
sium (Gibco/Invitrogen) for the smoke exposure. The cov-
ers were removed from the Petri dishes and they were
placed in a smoke exposure chamber designed to deliver a
consistent dose of diluted CS. CS was generated under
Federal Trade Commission (FTC)[40] smoking condi-
tions (35 ± 0.3 cc puff, one puff every 60 seconds, 2-sec-
ond puff duration with none of the ventilation holes
blocked) using a KC 5 Port Smoker (KC Automation,
Richmond, VA), from 2R4F reference research cigarette
(designed to represent the average 'lights' cigarette mar-
keted in the U.S. with FTC values of 9.7 mg 'tar' and 0.85
mg nicotine; University of Kentucky, Louisville, KY) using
FTC machine smoking conditions, or two leading com-
mercially available U.S. cigarette brands representative of
either the 'lights' (FTC values of 11 mg 'tar' and 0.8 mg
nicotine) or 'full-flavor' (FTC values of 15 mg 'tar' and 1.1
mg nicotine) styles of cigarettes. Cigarettes were smoked
to within 3 mm of the filter tip. All cigarettes had been
equilibrated at 23.9°C ± 1.1°C and 60% ± 2% relative
humidity for a minimum of 24 hours and a maximum of
14 days. The smoke exposure chamber was designed to
deliver smoke uniformly diluted with 5% CO2 in air and
passed through the cell exposure chamber at a constant
flow rate of 500 cc/min. Briefly, each 35 cc puff was first
drawn into a 250 cc round chamber containing 5% CO2
in air and mixed via a stir bar. The standard smoke dilu-
tion used in most of our experiments was 35 cc delivered
over 1 min in a 250 cc or 500 cc volume, and the intensity
of exposure was varied by varying the length of time the
cells spent in the exposure chamber (typically 15 min or
20 min). The time and distance that the smoke traveled
from the end of the cigarette to the exposure chamber was
minimized by using the shortest lengths of tubing possi-
ble between the parts of the apparatus. Mock-exposed
cells were treated under identical conditions as the
exposed cells except for the absence of a cigarette in the
smoking port. Following treatment or mock treatment,
the D-PBS covering the cells was aspirated and replaced
with 1 ml per chamber of fresh culture medium at 37°C.
The cells were placed in the 37°C, 5% CO2 incubator for
the times indicated.
Thapsigargin, tunicamycin, and dithiothreitol treatment
UPR-stimulating reagents thapsigargin, tunicamycin, and
dithiothreitol (DTT) were obtained from Sigma, St. Louis,
MO. Treatment conditions used in our experiments were
1 uM thapsigargin, 10 μg/mL tunicamycin, or 2 mM DTTBMC Cancer 2008, 8:229 http://www.biomedcentral.com/1471-2407/8/229
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added to the cell culture medium in DMSO (thapsigargin
and tunicamycin) or water (DTT), and the cells were
placed in the 37°C, 5% CO2 incubator for the times indi-
cated. In experiments where thapsigargin or tunicamycin
treatment followed smoke exposure, the PBS was
removed from the cell cultures immediately after smoke
exposure and replaced with fresh medium containing the
thapsigargin or tunicamycin, and placed in the 37°C, 5%
CO2 incubator for the times indicated.
Microarray analysis
Cells were harvested for total RNA extraction after either
mock or smoke treatment. The medium was aspirated and
the dishes were rinsed twice with 1 mL prewarmed PBS
per dish. After the second rinse, 350 ul of Buffer RLT (Qia-
gen Inc, Valencia, CA) was added per dish. NHBE cell
lysates were homogenized using a QIAshredder spin col-
umn and RNA extracted using Qiagen RNeasy spin col-
umns according to the manufacturer's protocol (Qiagen).
The eluted RNA was frozen and stored at -80°C. Microar-
ray data was generated at Expression Analysis (Durham,
NC). RNA integrity was assessed using capillary gel elec-
trophoresis (Agilent BioAnalyzer, Agilent Technologies,
Palo Alto, CA) to determine the ratio of 28s:18s rRNA in
each sample. The RNA quality of all samples was
extremely high with no RNA Integrity Number (RIN)
being less than 9.5 out of 10.0 RIN units (a detailed expla-
nation of RIN units can be found at http://www.chem.agi
lent.com/scripts/LiteraturePDF.asp?iWHID=37507). Two
micrograms of total RNA was reverse transcribed into
double stranded cDNA using an oligo(dT)/T7 promotor
chimeric primer, and in vitro transcribed using reagents
provided by Affymetrix (Santa Clara, CA). Fragmented
biotin-labeled cRNA at a concentration of 50 ng/ul was
hybridized to Affymetrix Human Genome U133 Plus 2.0
GeneChip® expression arrays according to the manufac-
turer's recommendations for a minimum of sixteen hours.
Post-hybridization washing and staining was performed
on the GeneChip® Fluidics Station 450 and arrays were
scanned with the GeneChip® Scanner 3000 7G, under the
control of the Affymetrix GeneChip® Operating Software
(GCOS). Preliminary expression data analysis was per-
formed by GCOS. Two-Group Comparisons with Permu-
tation Analysis for Differential Expression (PADE) was
used to determine differential gene expression between
CS-exposed and mock-exposed groups at each time point,
each group consisting of multiple arrays. PADE analysis
provides statistically valid summary measures including
false discovery rates along with transcript sets that are typ-
ically much more useful and indicative of differential
expression between groups than using techniques such as
p-values alone, corrected p-values, or p-values with fold
change estimates. A complete description of this type of
analysis can be found at the Expression Analysis website:
http://www.expressionanalysis.com/pdf/
PADE_TechNote_2005.pdf. A false discovery rate of 1%
and a fold-change level of 1.5 were used as cutoff values.
The full microarray data sets have been deposited accord-
ing to MIAME standards on the NCBI GEO (Gene Expres-
sion Omnibus) website: http://www.ncbi.nlm.nih.gov/
geo/ under the GEO accession numbers GSE10700 and
GSE10718.
PCR analysis of XBP1 splicing
RNA was harvested using the Qiagen RNeasy mini kit
according to manufacturer's instructions immediately.
First-strand cDNA synthesis was performed with the High
Capacity cDNA Reverse Transcription kit for RT-PCR
(Applied Biosystems, Foster City, CA). To amplify XBP1
mRNA (NM_005080), PCR was performed for 35 cycles
(95°C for 30s; 58°C for 30s; 72°C for 1 min) using the
PCR primers 5'-CTG GAA AGC AAG TGG TAG A-3' and 5'-
CTG GGT CCT TCT GGG TAG AC-3' with AmpliTag Cold
DNA polymerase (#N808-0241; Applied Biosystems).
Fragments representing spliced and unspliced XBP1 (398
bp and 424 bp, respectively) were visualized on 2% agar-
ose gels with ethidium bromide staining. NIH ImageJ
software (http://rsb.info.nih.gov/ij/, [41]) was used to
quantify gel band intensities.
Transfection of A549 Cells with ATF6 plasmid
A549 cells were seeded in 35 mm culture dishes at 1.2 ×
105 cells per dish. At 24 hours after the seeding, cells were
transfected with ATF6 expression plasmid ATF6/pCMV6-
XL5 (OriGene Technologies, Inc., Rockville MD, Catalog
# SC115551). Transfection was performed with Lipo-
fectamine LTX (Invitrogen catalog # 15338-100) accord-
ing to the manufacture's recommendation. Briefly, 2 μg of
the plasmid DNA was diluted in 400 ul serum-free
medium and mixed with PLUS Reagent (Invitrogen cata-
log #11514-015) at 1:1 ratio (DNA μg: PLUS vol. in μl).
The mixture was incubated at room temperature for 5
min. Lipofectamine LTX was then added to the DNA/
PLUS mixture and incubated at room temperature for an
additional 25 min. At the end of the incubation, the orig-
inal growth medium was removed and 2 ml of fresh pre-
warmed growth medium was added to each dish. The
DNA/PLUS/Lipofectamine complex was immediately
added to the appropriate culture dishes, gently mixed and
returned to the incubator for another 6 hours after which
the medium was replaced again with fresh pre-warmed
complete growth medium and the cells were returned to
the incubator until smoke exposure or DTT treatment 24
hours post-transfection. Control cells were transfected
with pCMV6-XL5 plasmid using the same procedure as
above.
Transfection of A549 cells with PERK siRNA
A549 cells were seeded in 100 mm2 culture dishes at 9 ×
105 cells per dish. At 20 hours after seeding, cells wereBMC Cancer 2008, 8:229 http://www.biomedcentral.com/1471-2407/8/229
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transfected with PERK siRNA oligos (Dharmacon, Lafay-
ette, CO, catalog # L-004883-00) or non-target siRNA oli-
gos (Dharmacon, catalog # D-001810-10) using
DharmaFECT1 transfection reagent (Dharmacon catalog
# T-2001-02). Briefly, 21 μl of DharmaFECT1 was diluted
in 679 μl of serum-free medium and was incubated at
room temperature for 5 minutes. In a separate sterile tube,
70 μl of siRNA oligos (20 μM stock) was mixed with 630
μl of serum-free medium and incubated at room temper-
ature for 5 minutes. The diluted DharmaFECT1 and
diluted siRNA oligos were then mixed together and incu-
bated at room temperature for another 20 minutes. At the
end of the incubation period, 12.6 ml of complete growth
medium was added to the mixture and 14 ml of this final
mixture was dispensed to each of the 100 mm2 dish after
the original growth medium was removed by aspiration.
The dishes were returned to the incubator for another 6
hours before the oligo-DharmaFECT1 containing
medium was replaced with fresh prewarmed complete
medium. The culture was then allowed to grow in the
incubator for another 20 hours when the cells were
trypsinized and reseeded in 35 mm2 dishes at 1 × 105 cells
per dish. The 35 mm2 dishes were returned to the incuba-
tor and the cells were allowed to grow for another 48
hours before smoke exposure or thapsigargin treatment.
Cell Lysis for Western Blots
Following treatment, the culture medium was aspirated,
cell monolayers were washed twice with cold D-PBS, 2
ml/dish, and 1 ml (per 106 cells) of RIPA cell lysis buffer
(Pierce, Rockford, IL) containing protease and phos-
phatase inhibitors was added to the monolayer. Cells
were dislodged using a cell scraper, transferred to an
eppendorf tube, vigorously pipetted, and left on ice for 25
minutes to allow complete lysis. The cell lysates were cen-
trifuged at 10,000 × g for 25 minutes and the supernatants
transferred to fresh eppendorf tubes. All manipulations
were done at 4°C. Protein concentration of the lysates
were determined against a commercially available protein
standard using the BioRad protein assay kit (both from
Bio-Rad Laboratories, Hercules, CA)
NHBE cell nuclear fractionation for ATF4 detection
NHBE cells (3rd passage) were seeded at 6 × 105 cells per
100 mm2 dish two days prior to the smoke exposure. On
the day of smoke exposure cells were trypsinized and
counted at 4 hours and 7 hours post-CS exposure or after
6 hours of incubation in media containing 1 μM thapsi-
gargin. The total cell numbers were calculated and used
for adjusting buffer volumes during cell compartment
fractionation. The cellular compartment fractionation was
carried out using the Qproteome Cell Compartment Kit
(Qiagen catalog # 37502) according to manufacturer's
instructions.
Western Blotting
Protein lysates were run on Criterion Tris-precast polyacr-
ylamide gels (Bio-Rad Laboratories) with SeeBlue Plus2
and Magic Mark protein standards (both from Invitrogen,
Carlsbad, CA) and transferred to a PDVF membrane using
a Criterion Blotter apparatus (Bio-Rad Laboratories) for
~40 min at room temperature using a transfer buffer con-
taining 10% methanol (Bio-Rad Laboratories). Primary
antibodies were from the following sources: Cell Signal-
ing Technology, Danvers, MA (eIF2α cat#9722, phospho-
eIF2α cat#3597, BiP cat#3183, Lamin A/C cat#2032 & α-
tubulin cat#2144), GeneTex, Inc., San Antonio, TX (eIF2A
(phospho S52)Cat # GTX24837), Santa Cruz Biotechnol-
ogy Inc., Santa Cruz, CA (ATF3 cat#sc-188, ATF4 cat#sc-
200), Abcam Inc., Cambridge, MA (GAPDH cat#ab8245,
α-tubulin cat#24246), Imgenex, San Diego, CA (ATF6
cat#IMG-273). Membranes were blocked with 5% BSA
(for eIF2α, phospho-eIF2α, ATF6, BiP and α-tubulin), 5%
BLOTTO (Pierce) for ATF3 and ATF4, and T-20 (Pierce)
for GAPDH for 1 hour at room temperature, and then
washed with TBST (Bio-Rad) for 3 × 10 min. Membranes
were placed in 5% BSA, 5% Blotto or T-20 buffer solution
containing the primary antibody (1:1000 dilution for
anti-eIF2α, anti-phospho-eIF2α, BiP, and Lamin A/C,
1:200 dilution for ATF3 and ATF4, 1:500 for ATF6, 1:2000
for α-tubulin, and 1:40,000 for GAPDH) and incubated at
4°C overnight with gentle shaking, followed by washes in
TBST for 3 × 10 min. Membranes were then placed in 5%
BSA, 5% Blotto or T-20 solution containing anti-rabbit-
HRP, or anti-mouse-HRP secondary antibody (Cell Sign-
aling Technology) at a 1:2000 dilution and incubated for
1 hour at room temperature with gentle shaking, after
which they were washed with TBST for 3 × 10 min. Blots
were developed using Western Lightning chemilumines-
cence reagent (Perkin-Elmer, Boston, MA) according to
manufacturer's instructions. NIH ImageJ software (http://
rsb.info.nih.gov/ij/, [41]) was used to quantify gel band
intensities.
Tissue Microarrays (TMAs)
Commercial Cancer/Normal Lung Tissue arrays were
acquired from Asterand (Detroit, MI). Arrays were con-
structed from formalin-fixed paraffin-embedded tissues
representing 120 normal and lung cancer cases. Each tis-
sue microarray contained 10 normal cases and 110 tumor
cases from a broad range of lung cancer types. Every tissue
sample was reviewed by a board certified pathologist to
confirm tissue type, diagnosis and optimal region for cor-
ing before use. Cores of 0.6 diameter were removed from
each selected sample and placed in a paraffin block using
a Beecher Manual Array instrument. Each case was repre-
sented in triplicate for a total of 360 cores. An H&E slide
of each array post construction was completed as a quality
control measure. Table 1 lists the pathological characteris-BMC Cancer 2008, 8:229 http://www.biomedcentral.com/1471-2407/8/229
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tics of these 120 formalin-fixed, paraffin-embedded archi-
val tissues from patients.
Antibodies and immunohistochemical analysis
Identical TMAs were immunostained with one of the fol-
lowing antibodies: a) a rabbit monoclonal anti-BiP anti-
body (Cell Signaling Technology, Danvers MA, cat. #
3177) recognizing BiP (C50B12) from rabbits immunized
with a synthetic peptide derived from the sequence
around Gly584 of human BiP (used at 1:200 dilution and
a concentration of 1 μg/ml); b) a mouse monoclonal anti-
EIF2 antibody (Cell Signaling Technology cat. #2103) rec-
ognizing eIF2α (L57A5) from mice immunized with puri-
fied recombinant human eIF2α (used at 1:50 dilution and
a concentration of 0.1 μg/ml); c) a rabbit monoclonal
anti-phospho-EIF2 antibody (Cell Signaling Technology
cat.# 3597) recognizing Ser51 (used at 1:50 dilution and
a concentration of 1 μg/ml); d) an irrelevant rabbit IgG
antibody control (Jackson ImmunoResearch, West Grove,
PA) (used at a concentration of 1 μg/ml). Prior to anti-
body staining, slides were deparaffinized in 3 changes of
xylene and rehydrated in graded ethanol. All slides were
subjected to antigen unmasking in 10 mM citrate buffer,
pH 6.0, quenching in 3% H2O2 and blocking prior to
incubation with primary antibodies overnight at 4°C. Fol-
lowing incubation with the primary antibodies, detection
was performed using the ABC Elite Kit (Vector Laborato-
ries, Burlingame, CA) with either a biotinylated goat anti-
rabbit secondary antibody or a biotinylated goat anti-
mouse secondary antibody (Jackson ImmunoResearch).
Both eIF2α mouse monoclonal and BiP rabbit mono-
clonal antibodies from Cell Signaling Technology had
previously been validated at the company using human
breast carcinoma samples and multi-tissue arrays. The
sequence specificity of the BiP antibody was verified using
peptide blocking. The EIF2 ?antibody was raised against a
fusion protein and thus was not validated with peptide
blocking. The antibody did give the expected expression
and subcellular localization. Human breast carcinoma
slides used as a control were obtained from Newcomer
Supply (Madison, WI). The anti-phospho-eIF2α antibody
has been validated at Cell Signaling Technology using 3T3
-/+ thapsigargin cell pellets, human breast carcinoma
samples and a multi-tissue array. Phospho-specificity of
the antibody was confirmed using lambda phosphatase
pre-treatment of tissue sections, and sequence specificity
was verified using peptide blocking.
Clinicopathological variables
The following variables were correlated with protein
expression: a) tumor stage, b) age at tumor excision, c)
gender, d) ethnicity, e) smoking status (i.e., never user,
occasional user, former user, current user); f) number of
cigarettes per day, and g) smoking duration. Staging
adhered to the AJCC pTNM (tumor-node-metastasis)
staging system and included both clinical and histological
data.
Staining criteria and statistical analyses
Tumor cells and non-tumor cells were scored separately
for percent immunohistochemical reactivity and staining
intensity for BiP, eIF2α, and phospho-eIF2α expression.
The percentage of cells staining positive was assigned one
of the following grades: (0) < 5%; (1) 5–25%; (2) 25–
50%; (3) 50–75%; (4) > 75%. Staining intensity was inde-
pendently graded on the following scale: (0) none; (1)
weak; (2) moderate; (3) strong; (4) intense. In order to
more accurately reflect the synergistic contribution of
both criteria to overall protein expression, the product of
the percentage and intensity scores was used to generate
an immunohistochemical staining index (ISI) for each
cellular component (i.e., tumor and non-tumor) of an
individual tissue specimen [42,43]. Staining was inde-
pendently assessed by two pathologists. Measurements
were made in triplicate. For purposes of statistical analy-
sis, triplicate measurements were represented by their
Table 1: Clinicopathological characteristics of the assessed lung cancers.
Clinical Variable Subcategory Number of Samples
Age at excision: 32–76 (mean = 60.2 yrs)
Small Cell Carcinoma Small cell carcinoma 5
Non-Small Cell Carcinoma 93
Adenocarcinoma 39
Adenosquamous carcinoma 12
Squamous cell carcinoma 37
Large cell carcinoma 4
Bronchioloalveolar carcinoma 1
Mixed Carcinoma Types 12
Carcinoid tumor 2
Carcinoma 3
Clear cell carcinoma 1
Undifferentiated carcinoma 2
Malignant mesothelioma 4BMC Cancer 2008, 8:229 http://www.biomedcentral.com/1471-2407/8/229
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mean. To compare mean ISI levels between each carci-
noma diagnostic group with the normal group, one-way
analyses of variance followed by Dunnett's tests were
used. To compare the ISI levels in the tumor and normal
cell compartments of each specimen, repeated measures
analyses of variance followed by Tukey's tests were used.
A result was considered statistically significant if the
resulting P value was less than or equal to 0.05.
Results
Generation of a CS Gene Expression 'Signature' in NHBE 
cells
Despite the fact that commercial brands of cigarettes sold
in the U.S. differ in terms of tobacco blends, flavorings,
general construction attributes, and 'tar'/nicotine yields,
epidemiological studies indicate essentially no significant
difference in lung cancer risk among long-term smokers of
different cigarette brands or styles (i.e., ultralights, lights,
or full-flavor) [44-48]. The obvious conclusion from these
data is that the chemical composition and overall toxicity
of all brands and styles of currently available U.S. ciga-
rettes are generally comparable. Therefore, it is reasonable
to assume that these cigarettes also have a similar molec-
ular impact on cells and tissues, at least with respect to
those genes/proteins relevant to disease. In order to link
one or more of these genes/proteins to the various patho-
logical states observed in smokers a logical first step
would be to first generate a generic CS-specific gene or
protein expression 'signature' that is reflective of cigarettes
regardless of brand or style. Consequently, NHBE cells
were exposed in vitro to whole smoke from three different
cigarettes: the 2R4F Kentucky Reference Cigarette which is
a 'lights' type cigarette (FTC values of 9.7 mg 'tar'/0.85 mg
nicotine), and two leading U.S. commercial brands repre-
sentative of a 'full flavor' type (Brand A: FTC values of 15
mg 'tar'/1.1 mg nicotine) and a 'lights' type (Brand B: FTC
values of 11 mg 'tar'/0.8 mg nicotine).
Using the exposure chamber as described in the Methods
section, NHBE cells were exposed to air or CS generated
under FTC smoking conditions for 15 min, which for the
CS-exposed samples resulted in an average total particu-
late matter (TPM) deposition per cigarette of 3.14 μg/cm2
(Brand A, 'full-flavor' type), 2.70 μg/cm2 (Brand B, 'lights'
type), and 2.56 μg/cm2 (2R4F reference cigarette). In vivo
studies measuring particulate matter distribution in the
human lung have estimated that smoking a single 10 mg
'tar' cigarette results in the deposition of between 0.74 to
1.94 μg of particulate matter/cm2 [49,50]. Subsequent to
the 15 min treatment with either CS or air, the cells were
subjected to a post-exposure washout period (incubation
in fresh media) for 2, 4, or 24 h after which the cells were
lysed and RNA extracted for microarray analysis. Viability
of CS-treated cells was typically greater than 50% that of
air-treated controls when assessed by trypan blue exclu-
sion.
Gene expression data from the 'full-flavor' Brand A,
'lights' Brand B, and the 2R4F reference cigarette at each of
the three post-exposure time points was compared to data
from the corresponding air-exposed control samples to
determine differential gene expression patterns resulting
from CS exposure. Perturbations in gene expression com-
mon to all three cigarette variants were taken to represent
the common CS signature for each time point. Specific
gene lists comprising CS signatures for 2 h, 4 h and 24 h
are provided in additional file 1 – Supplemental Table
S1: Cigarette smoke signature genes. The high-strin-
gency inclusion criteria used to generate these lists (see
Methods section) greatly increases the probability that the
genes will be highly relevant to tobacco-related impact. To
elucidate the major biological processes represented by
the CS signatures at each time point, the gene lists were
subjected to Functional Annotation Enrichment Analysis
using statistical tools available at the newly-updated Data-
base for Annotation Visualization and Integrated Discov-
ery (DAVID) web site http://david.abcc.ncifcrf.gov/. CS
signature gene lists were uploaded to DAVID where they
were functionally annotated and clustered. We used Gene
Ontology (GO) annotations to explore biological signifi-
cance of the gene lists rather than curated pathway data
such as KEGG pathways because more thorough annota-
tion information is available for GO classes than for
KEGG pathway involvement. For example, 72% of the
genes in a test list had GO Biological Process annotation
as opposed to only 21% represented in KEGG pathways.
Biological processes significantly over-represented in the
uploaded gene lists were identified and clustered accord-
ing to GO Biological Process categories. The mean p-value
for each cluster was determined and used to list the clus-
ters in order of significance (additional file 2 – Supple-
mental Table S2: Functional annotation clustering of
cigarette smoke signature genes). Examination of the
most significant clusters (p-value < 0.01) for the 4 h upreg-
ulated CS signature revealed several processes characteris-
tic of exposure to xenobiotics such as response to stress,
response to chemical stimulus, and response to abiotic
stimulus. Notably, some of the lowest p-values at 4 h are
the GO categories 'response to unfolded proteins' and
'protein folding'. Based on this observation, and because
it is increasingly clear that the UPR can play a pathogenic
chronic role in a wide range of diseases including cancer
[12-14,51] we decided to further assess the effects of CS
treatment on UPR pathway components in lung cells.
CS treatment induces the phosphorylation of eIF2α by 
PERK in normal human lung cells
The canonical pathway for ER stress activation of the UPR
begins with the dissociation of BiP from PERK, resultingBMC Cancer 2008, 8:229 http://www.biomedcentral.com/1471-2407/8/229
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in PERK autophosphorylation. Upon activation, PERK
phosphorylates eIF2α at serine-51, a key step in the proc-
ess which inhibits translation by preventing the recruit-
ment of the initiator methionyl tRNA to ribosomes (for
review see [52]). The suppression of protein translation
via phosphorylation of both PERK and eIF2α in rodent
cells in response to treatment with cigarette smoke-bub-
bled PBS has recently been demonstrated [31]. However,
in order to investigate PERK-dependent eIF2α phosphor-
ylation in diploid normal human bronchial epithelial
(NHBE) lung cells as well as malignant human lung cells
(A549) treated with a relatively brief exposure to whole
smoke, we assessed the response of cells exposed to CS
from 2R4F reference cigarettes as well as 'full-flavor' Brand
A, 'lights' Brand B for the transient phosphorylation of
eIF2α. Figure 1, Panel A shows that exposure of NHBE to
CS from 2R4F reference cigarettes resulted in the rapid
phosphorylation of eIF2α within 30 minutes, which
peaked between 30–60 minutes and diminished to mock-
treated control levels by 4 hours. Equivalent results were
seen for A549 cells (data not shown). This is a similar time
course to that seen after exposure to thapsigargin (1 μM),
a potent inducer of ER stress and eIF2α phosphorylation
(Figure 1, Panel B). Figures 1A and 1B also show that dur-
ing the time period studied (0–4 hours after CS exposure)
there were no significant changes in protein levels of total
eIF2α after exposure to either CS or thapsigargin. Similar
to the results observed with 2R4F cigarettes, CS generated
from the 'full flavor' Brand A and 'lights' Brand B cigarettes
also induced the rapid eIF2α phosphorylation with essen-
tially the same time course as that observed for 2R4F (data
not shown), suggesting that activation of the UPR path-
way is common to all types of cigarettes.
In addition to PERK, three other kinases capable of phos-
phorylating eIF2α (PKR, HRI, and GCN2, reviewed in ref-
erence [52]) have been identified in mammals. Although
current understanding indicates that these other kinases
are regulated by different stress stimuli [52], their catalytic
domains are homologous. Thus, phosphorylation of
eIF2α by any of these four kinases results in similar down-
stream events, including translation attenuation and acti-
vation of transcriptional programs that augment the cell's
ability to cope with problematic conditions such as the
accumulation of unfolded proteins, amino acid depriva-
tion, or oxidative stress [52]. However, PERK-induced
activation of eIF2α is believed to occur exclusively upon
the induction of ER stress [11]. Consequently, in order to
show that CS treatment induces ER stress, it is important
to demonstrate the dependence of CS-induced phosphor-
Induction of eIF2α phosphorylation in NHBE cells by cigarette smoke and thapsigargin Figure 1
Induction of eIF2α phosphorylation in NHBE cells by cigarette smoke and thapsigargin. Panel A: NHBE cells 
were exposed to air (M = mock treatment) or 2R4F cigarette smoke with 35 cc puffs diluted in 250 cc air (CS = smoke treat-
ment) for 20 minutes. Cells were then placed in fresh medium and returned to the incubator for the time periods specified. 
Western blots of whole cell lysates were probed with antibodies to phosphorylated eIF2α, eIF2α, and GAPDH as a loading 
control. C = untreated control. Panel B: NHBE cells were treated with either 1 uM thapsigargin in DMSO (T), or DMSO (VC 
= vehicle control) for the times specified. Western blots of whole cell lysates were probed with antibodies to phosphorylated 
eIF2α, eIF2α, and GAPDH. C = untreated control.BMC Cancer 2008, 8:229 http://www.biomedcentral.com/1471-2407/8/229
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ylation of eIF2α phosphorylation on PERK. Thus, A549
cells were transiently transfected with a plasmid contain-
ing siRNA designed to silence PERK, and then exposed to
CS or to thapsigargin as an activation control. As shown in
Figure 2, PERK siRNA transfected A549 cells show notably
reduced phosphorylation of eIF2α when treated with CS
(Panel A) or thapsigargin (Panel B), indicating that PERK
is the major effector of CS-induced phosphorylation of
eIF2α in both these systems. Total eIF2α levels remained
constant in all samples regardless of treatment conditions.
Effect of CS on ATF4 levels and expression of ATF4-
dependent genes
In addition to transiently suppressing protein translation
during ER stress, a second function of PERK phosphoryla-
tion of eIF2α is the upregulation of genes integral to the
UPR pro-survival response that promote protein folding
and redox homeostasis [53]. For example, eIF2α phos-
phorylation promotes the induction of activating tran-
scription factor 4 (ATF4) through a mechanism that relies
upon unique features in its 5' untranslated region [54].
ATF4 accumulates in the nucleus and upregulates genes
that attempt to adapt the cell to ER stress such as activating
transcription factor 3 (ATF3), a member of the ATF/CREB
family of basic-region leucine zipper (bZIP) proteins
[55,56], or the pro-apoptotic transcription factor CCAAT/
enhancer binding protein-homologous protein (CHOP)
[57]. CHOP and ATF3 in turn coordinate the upregulation
of GADD34 which provides a feedback inhibitory effect
on UPR [58].
Figure 3 (Panel A) shows an increase in the level of
nuclear ATF4 in NHBE cells in response to CS treatment at
4 hrs post-exposure which diminishes by 7 hrs. In addi-
tion, Figure 3 shows that both GADD34 (Panel B) and
ATF3 (Panel C) protein levels also increase in CS-treated
cells. ATF3-induced expression has a similar time-course
as ATF4 (i.e., peaking around 4 hrs post-exposure) while
peak GADD34 expression occurs between 7–12 hrs post-
exposure. Consistent with this protein data, the array pro-
files of cigarette smoke signature genes shown in Addi-
tional file 1 – Supplemental Table S1 shows that the
mRNA transcripts for CHOP (also denoted DDIT3), ATF3,
and GADD34 (also denoted PPPIR15A) are upregulated
by CS treatment.
Effect of CS exposure on the ATF6 branch of UPR in 
human lung cells
In addition to PERK, a second UPR effector arm is acti-
vated by proteolytic cleavage of the 90 kDa ATF6 protein
and release of a functional 50 kDa transcription factor.
Our initial analysis indicated that the basal level of ATF6
expression in A549 cells was below detectable levels (data
not shown). Thus, in order to assess the effect of CS on
ATF6 cleavage we constructed a full length ATF6/pCMV6
expression plasmid and transfected it into A549 cells
which were then exposed to CS. Since robust detection of
the 50 kDa end product is difficult as it is unstable and
rapidly degraded [59], we monitored the disappearance of
the 90 kDa ATF6 protein to assess its activation. Figure 4
(Panel A) shows that treatment of ATF6-transfected A549
cells with DTT, a potent inducer of ER-stress and the UPR
due to its disruption of intramolecular disulfide bonds,
results in the disappearance of the 90 kDa protein by 1 hr.
Similarly, Figure 4 (Panel B) shows that treatment of
ATF6-transfected A549 cells with CS also results in disap-
pearance of ATF6 starting at 2 h post-CS exposure and
continuing to at least 4 h post-exposure. The reduction in
the 90 kDa ATF6 protein could also be due to increased
degradation or reduced synthesis. However, when the
array data was assessed to determine changes in the levels
of three genes whose transcription is dependent on acti-
vated ATF6 (i.e., BiP, XBP1, and grp94) [60], we found
that both XBP1 and BiP transcript levels are elevated in
response to CS treatment (Figure 5). Thus, these data sup-
port the conclusion that CS-treatment activates the ATF6-
signaling pathway.
Effect of CS exposure on the expression of BiP in human 
lung cells
The transient accumulation of misfolded proteins, a key
indicator of ER stress, results in the dissociation of the ER-
resident master chaperone regulator BiP from all three ER
resident sensors (i.e., PERK, IRE1 and ATF6) triggering
their activation and subsequent induction of various func-
tions of the UPR that provide the cell with a mosaic of
options to counter ER stress and reestablish homeostasis
[61,62]. For example, when ER stress becomes chronic,
one pro-survival mechanism is to upregulate the master
regulator, BiP, which allows the cell to endure an
increased level of unfolded proteins and forestall apopto-
sis [63,64]. In one recent publication, Hengstermann and
Muller [31] saw a modest increase in BiP RNA levels in
mouse cells after 4 h continuous treatment with PBS into
which CS was previously bubbled [31]. A second report by
Kelsen et al, [30] observed increased BiP protein levels in
virally transformed human bronchial epithelial cells after
24 h continuous treatment with 15% cigarette smoke
extract. In contrast to these studies, our results show that
when A549 cells (Figure 6, Panel A) or NHBE cells (data
not shown) were briefly exposed to freshly generated
whole CS for 20 min, Western blot analysis showed no
increase of BiP protein levels up to 72 h post-exposure.
Control cells treated with thapsigargin show strong induc-
tion of BiP by 24 h. We speculated that this apparent dis-
crepancy in BiP expression could be due to the fact that we
exposed short-term cultures of untransformed NHBE cells
(as opposed to rodent cells or virally-transformed bron-
chial cells). Alternatively, since there are significant differ-
ences between our exposure parameters and thoseBMC Cancer 2008, 8:229 http://www.biomedcentral.com/1471-2407/8/229
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Dependence of eIF2α phosphorylation on PERK in A549 cells treated with cigarette smoke (and thapsigargin Figure 2
Dependence of eIF2α phosphorylation on PERK in A549 cells treated with cigarette smoke (and thapsigargin. 
Panel A: A549 cells were transfected with control siRNA (lanes 3 and 4) or PERK siRNA (lanes 5 and 6) as described in 
Methods. 24 h post-tranfection the cells were exposed to air (lanes 1, 3, and 5) or 2R4F cigarette smoke with 35 cc puffs 
diluted in 250 cc air (lanes 2,4, and 6) for 20 minutes. Cells were then placed in fresh medium and returned to the incubator 
for the time periods specified. Western blots of whole cell lysates were probed with antibodies to phosphorylated eIF2α, 
eIF2α, and GAPDH as a loading control. Panel B: A549 cells were transfected with control siRNA (lanes 3 and 4) or PERK 
siRNA (lanes 5 and 6) as described in Methods. 24 h post-tranfection the cells were treated with either 1 uM thapsigargin in 
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detailed in these two recent reports, a more likely explana-
tion may be that the brief CS treatment protocol (20 min
followed by washout and addition of fresh medium) used
in our experiments resulted in an abbreviated UPR
response that fails to trigger BiP upregulation. Since BiP
induction is a relatively late event in the UPR signaling
cascade, differing stress-inducing exposure conditions can
lead to short term perturbations without durable long-
term changes [12]. To test this idea, we prepared CS-bub-
bled media (CSE) according to the procedure used by
Hengstermann and Muller [31] and treated NHBE cells for
24 h in 15% or 30% CSE. Moreover, instead of our usual
procedure, we also exposed NHBE cells to CS for 20 min,
except that after this treatment, the cells were not placed
in fresh media but were incubated in the CS-containing
medium for another 24 hrs. We observed that both of
these much longer exposure procedures did result in the
upregulation of BiP, although not to the degree seen with
the more potent ER-stress inducer thapsigargin (Figure 7).
We note that when either A549 or NHBE cells are treated
with 1 μM thapsigargin continuously for 72 h, BiP expres-
sion is still only seen after 24 hours post-treatment, indi-
cating that BiP induction is a much later consequence of
ER stress than is eIF2α phosphorylation in these cells (see
Figure 6, Panel B). Consequently, these data, while agree-
ing with previous reports showing that BiP expression is
induced by CS [30,31], clearly show that BiP induction
can be modulated depending on level and duration of
Effect of CS on ATF4 pathway Figure 3
Effect of CS on ATF4 pathway. Panel A: NHBE cells were exposed to air (M = mock treatment) or 2R4F cigarette smoke 
with 35 cc puffs diluted in 250 cc air (CS = smoke treatment) for 20 minutes. Cells were then placed in fresh medium and 
returned to the incubator for the time periods specified. Nuclear extracts were prepared as described in the Methods section. 
Western blots of nuclear fractions were probed with antibodies to ATF4 and Lamin A/C, a nuclear antigen, as a loading con-
trol. Panel B: NHBE cells were exposed to air (M = mock treatment) or 2R4F cigarette smoke with 35 cc puffs diluted in 250 
cc air (CS = smoke treatment) for 20 minutes. Cells were then placed in fresh medium and returned to the incubator for the 
time periods specified. Western blots of whole cell lysates were probed with antibodies to GADD34 and α-tubulin as a loading 
control. Panel C:A549 cells were exposed to air (M = mock treatment) or 2R4F cigarette smoke (CS = smoke treatment) for 
20 minutes with 35 cc puffs diluted in 250 cc air. Cells were then placed in fresh medium and returned to the incubator for the 
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stress-inducing conditions. It has been shown that differ-
ent cell types and different stress conditions can selec-
tively activate one or more of the ER sensors [65].
Therefore, the induction of each UPR component (e.g.,
BiP) is likely to be dependent on its intrinsic set-point for
biological activation, specific cell context, and the defined
ability of an agent to induce ER stress over time.
Effect of CS exposure on the IRE1 branch of UPR in 
normal human lung cells
The third UPR activation pathway is mediated by a cas-
cade of events triggered by the dimerization and auto-
phosphorylation of the IRE1 transmembrane protein.
Under non-stressful conditions, IRE1 is inactive, however
upon ER stress the conformational alteration of IRE1 via
phosphorylation exposes a ribonuclease capability that
removes an intron from XBP1 mRNA (denoted XBP1S),
resulting in the generation of a functional protein that is a
potent transcriptional regulator of genes involved in pro-
Effect of CS on proteolytic cleavage of ATF6 Figure 4
Effect of CS on proteolytic cleavage of ATF6. Panel A: A549 cells were transfected with a plasmid expressing ATF6 
(lanes 2 and 4, indicated by +), or a control plasmid (lanes 1 and 3), then treated with 2 mM DTT for 1 h (lanes 3 and 4) or left 
untreated (lanes 1 and 2). Western blots of whole cell lysates were probed with antibodies to ATF6 and α-tubulin. Panel B: 
All lanes show lysates from A549 cells transfected with a plasmid expressing ATF6. Cells were exposed to air (M = mock treat-
ment) or 2R4F cigarette smoke (CS = smoke treatment) for 20 minutes with 35 cc puffs diluted in 250 cc air. Cells were then 
placed in fresh medium and returned to the incubator for the time periods specified. Western blots of whole cell lysates were 
probed with antibodies to ATF6 and α-tubulin. Gel bands were quantified as described in the Methods section. CS treatment 
resulted in a 23% and 26% decrease in ATF6 90 kDa protein at 2 and 4 h respectively (lane 5 compared to lane 6, lane 7 com-
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Expression of BiP, XBP1, and grp94 in CS-treated human lung cells Figure 5
Expression of BiP, XBP1, and grp94 in CS-treated human lung cells. NHBE cells were exposed to air (Mock), 2R4F 
cigarette smoke with 35 cc puffs diluted in 500 cc air (2R4F), or Brand B cigarette smoke with 35 cc puffs diluted in 500 cc air 
for 15 minutes. Cells were then placed in fresh medium and returned to the incubator for the time periods specified prior to 
RNA extraction. Four separate microarray representing four separate samples were used to analyze each condition. Mean 
intensity values are shown. * = p < 0.01 when compared to Mock.BMC Cancer 2008, 8:229 http://www.biomedcentral.com/1471-2407/8/229
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tein folding and degradation, two necessary mechanisms
needed to restore ER homeostasis. The impact of CS expo-
sure on XBP1 splicing was assessed. First, we determined
the ability of A549 cells to undergo typical XBP1 splicing
upon ER stress. Figure 8 (Panel A, lanes 1–4) shows that
under non-stressed conditions (i.e., air exposure) only the
unspliced form of XBP1 mRNA is detectable during the
time-frame examined (30 min – 4 h) as expected. Figure 8
(Panel A, lanes 5–12) show that when A549 cells are
exposed either to the ER stressors thapsigargin (which
Effect of thapsigargin and cigarette smoke on expression of BiP Figure 6
Effect of thapsigargin and cigarette smoke on expression of BiP. Panel A: A549 cells were treated with 1 mM thap-
sigargin for the time periods specified. U = untreated cell control; V = vehicle (DMSO) control; T = thapsigargin. Panel B: 
A549 cells were cells were exposed to air (M = mock treatment) or 2R4F cigarette smoke (CS = smoke treatment) for 20 
minutes (35 cc puffs were diluted in 250 cc air), after which the cells were placed in fresh medium and returned to the incuba-
tor for the time periods specified. Western blots of whole cell lysates were probed with antibodies to BiP and GAPDH. TC = 
thapsigargin treated cells as a positive internal control for Panel B.
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BiP expression in normal human lung cells treated with CS long term treatment Figure 7
BiP expression in normal human lung cells treated with CS long term treatment. NHBE cells were exposed to 
either 15% or 30% 2R4F cigarette smoke extract (CSE) prepared as described in (ref), or exposed to 2R4F cigarette smoke 
(CS) for 10 or 20 minutes (35 cc puffs were diluted in 250 cc air), after which the cells were immediately returned to the incu-
bator without a media change for the time periods specified. C = untreated control.BMC Cancer 2008, 8:229 http://www.biomedcentral.com/1471-2407/8/229
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inhibits the ER Ca2+ pump) or tunicamycin (which blocks
N-linked glycosylation), there is a significant increase in
XBP1S starting at 30 minutes and continuing for up to 4
hrs post-exposure with a concomitant decrease in the
unspliced form. In contrast, however, upon exposure to
2R4F CS the XBP1 mRNA remains in its unspliced form
(Panel B, lanes 1–4) during the 0 – 4 h post-exposure
assessment period. Indeed, when CS-exposed samples
collected up to 24 h post-exposure were analyzed, no
splicing of XBP1 was observed (data not shown).  For the
extent of splicing, see Additional File 3.
To determine if the lack of splicing is due to a minimal
impact of CS on IRE1 activation or active interference with
the splicing mechanism, we performed a dual-treatment
experiment in which A549 cells were first treated with CS
and subsequently with thapsigargin or tunicamycin. If the
inhibition of XBP1 splicing by CS is a dominant effect
then the observed ability of UPR-inducing agents to pro-
mote splicing should also be compromised. Figure 8
(Panel B) shows that when A549 cells were exposed to CS
and subsequently treated with either thapsigargin or tuni-
camycin, the observed XBP1S  levels were significantly
diminished, indicating that CS exerts a potent suppressive
effect upon XBP1 mRNA splicing (e.g., compare Panel B,
lanes 5–12 with Panel A, lanes 5–12). In order to confirm
that this suppression was not restricted to malignant lung
cells, NHBE cells similarly treated with either thapsigargin
or tunicamycin and exposed to 2R4F CS displayed an
almost identical pattern of XBP1 splicing suppression
(data not shown). In order to confirm that this suppres-
sion was not restricted to 2R4F, we examined two popular
commercial U.S. brands of 'full-flavor' and 'lights' ciga-
rettes for suppression of XBP1 splicing and observed
essentially identical results to that of 2R4F (data not
shown). Thus, these data indicate that the ability of CS to
suppress XBP1 splicing is not cell or cigarette type specific
but more likely due to a general property of CS exposure.
Since CS as well as thapsigargin and tunicamycin can
induce eIF2α-phosphorylation to a similar degree and
within a similar time frame (e.g., see Figures 1A and 1B
above for CS and thapsigargin respectively; tunicamycin
data not shown), the suppressive effect of CS on XBP1
splicing is not a global inhibitory effect on other UPR
effector arms. Indeed, treatment with both CS and thapsi-
gargin appears to induce higher levels of eIF2α phospho-
rylation than either treatment alone, i.e. the effects appear
to be additive (data not shown).
Our microarray data provide additional results to support
the observation that the CS-induced suppression of XBP1
splicing has biological relevance. Since XBP1 alone or in
Cigarette smoke inhibits XBP1 splicing Figure 8
Cigarette smoke inhibits XBP1 splicing. A549 cells were exposed to air (Panel A, mock treatment) or 2R4F cigarette 
smoke (Panel B) for 20 minutes with 35 cc puffs diluted in 250 cc air. Cells were then placed in fresh media with or without 1 
uM thapsigargin or 10 μg/ml tunicamycin for the time periods specified, followed by cell lysis and RNA purification. Spliced and 
unspliced XBP1 mRNA was detected using PCR methodology. Spliced XBP1 is 398 base pairs and the unspliced variant is 434 
base pairs. For each lane the extent of splicing was quantified as described in the Methods section and is presented in additional 
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conjunction with ATF6 controls the expression of a
number of UPR-relevant genes (e.g., EDEM, HRD1,
HERPUD1, ERdj3, P58IPK, ERdj4, and RAMP4 [19]), we
conjectured that the inhibition of XBP1 splicing by CS
would also prevent these transcripts from being expressed
or upregulated. Of these seven genes, five of them (i.e.,
EDEM, HRD1, ERdj3, P58IPK, and RAMP4) showed no
increase in expression above baseline (data not shown).
The only XBP1 specific genes that showed an increase
upon CS exposure were ERdj4 (DNAJB9) and HERPUD1,
which increased 4-fold and 2.5-fold, respectively, over
their expression levels in mock-treated cells at four hours
post-exposure. Whether this indicates that there are addi-
tional mechanisms that complement XBP1 activation that
can result in the expression of ERdj4 and HERPUD1 (as
has been reported for HERPUD1 [66]), or if minimal
amounts of spliced XBP1 are sufficient to induce their
expression, remains to be determined. We note that Heng-
stermann and Muller [31] also found a lack of XBP1 splic-
ing but concluded from their data that activation of IRE1
(which induces XBP1 splicing) by CS is negligible. How-
ever, our data suggest that the lack of XBP-1 splicing may
in fact be due a direct inhibition by CS. Additional
research should clarify the biological significance of the
impact of CS on the IRE1-XBP1 pathway.
Contribution of vapor and particulate phase constituents 
to eIF2α phosphorylation
CS is composed of a vapor phase and a particulate phase.
The vapor phase is arbitrarily defined as that portion of
smoke that passes through a Cambridge glass fiber filter,
while the particulate phase is that portion that is retained
by the filter [67]. The vapor phase is primarily a mixture
of gases (i.e., nitrogen, oxygen, and carbon dioxide) as
well as volatile and semi-volatile compounds such as car-
bon monoxide, acetone, nitrogen oxides, while the partic-
ulate phase contains a wide variety of condensed organic
compounds (i.e., 'tar') that include nicotine and a large
number of toxins, carcinogens, cocarcinogens, mutagens,
and reactive organic and inorganic molecules [67]. This
particulate phase contains the majority of tobacco smoke
compounds [at least 80] for which there is sufficient evi-
dence of carcinogenic potential in humans [68-70]. Pre-
sumably, the inherent chemical complexity of cigarette
smoke results in an equally complex biological response
involving a number of signaling pathways and check-
points that respond to cellular and genomic stress in
exposed tissues [71]. Few studies have attempted to
address the synergistic relationships between the thou-
sands of individual compounds that constitute the vari-
ous classes of carcinogens in the vapor and particulate
phases of tobacco smoke on gene expression. Thus, we
assessed whether the fractionated vapor and particulate
phases of CS from 2R4F cigarettes were also capable of
inducing eIF2α phosphorylation as was whole CS. Figure
9 shows that the vapor phase was as efficient at inducing
eIF2α phosphorylation in NHBE cells as was whole
smoke. In contrast, the particulate phase appeared to be
much less efficient at inducing eIF2α phosphorylation
than either the vapor phase or whole CS. As previously
observed for whole CS, there was no alteration in the total
level of eIF2α after exposure to either the vapor or partic-
ulate phases of CS.
Antioxidants prevent activation of UPR by CS
The results shown in Figure 9 indicated that the vapor
phase is as efficient as whole CS in inducing ER stress and
the phosphorylation of eIF2α. Since a primary constituent
of the vapor phase of CS is a large amount of highly reac-
tive organic and inorganic substances that either are free
radicals or reactive species (such as ￿O2
-, ￿NO, ￿OH, etc),
and more stable organic reactive species/oxidants (such as
phenols, hydroquinone, epoxides, etc.) that can cause a
marked imbalance in an individual's redox state and an
overall increase in oxidative stress in the respiratory tract
[72-75], we were interested in determining if free radical
scavengers could effectively suppress the induction of
eIF2α phosphorylation and the activation of the UPR pro-
gram. Figure 10 shows that the thiol N-acetyl-L-cysteine
(NAC), a potent free radical scavenging compound with
antioxidant activity, can completely prevent CS-induced
phosphorylation of eIF2α at 1 h or 4 h post-exposure in
A549 cells. NAC is freely taken up by cells, and can impact
a broad range of compounds, many of which cause some
form of oxidative stress. For example, NAC can scavenge
several reactive oxygen species (ROS) generated in CS
such as ￿O2
-, ￿OH, and H2O2, as well as directly bind and
attenuate various reactive CS compounds that can gener-
ate free radicals intracellularly (e.g. aldehydes, epoxides,
quinones, etc.). Figure 10 also shows that treatment with
reduced glutathione (GSH), a free radical scavenger that
does not cross the cell membrane, also suppresses the
ability of CS to induce eIF2α phosphorylation.
Contribution of vapor and particulate phase constituents 
to inhibition of XBP1 splicing
Figure 11 shows A549 cells exposed to particulate phase,
vapor phase, and whole smoke from the reference ciga-
rette 2R4F and treated with thapsigargin to assess inhibi-
tion of splicing. Similar to that observed with eIF2α
phosphorylation, the vapor phase was as efficient at sup-
pressing XBP1 splicing as whole smoke. In contrast, the
particulate phase of cigarettes appeared not to inhibit
splicing, suggesting that the inhibitory effect of CS is due
to one or more vapor phase components.
Expression of phospho-eIF2α, eIF2α, and BiP in human 
lung cancers
The data presented above indicate that in vitro exposure of
lung cells to CS induces the phosphorylation of eIF2α butBMC Cancer 2008, 8:229 http://www.biomedcentral.com/1471-2407/8/229
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does not increase the expression of either total eIF2α or
the major ER-stress induced chaperone protein BiP up to
24 hrs post-exposure. In order to determine the expression
levels of these proteins in vivo, we next examined archival
specimens of lung cancers. Expression of phospho-eIF2α,
eIF2α, and BiP was assessed by immunohistochemistry
on tissue arrays containing 360 cores representing 120 dif-
ferent histopathological classes of human lung neoplasms
Relative effect of vapor and particulate ('tar') phases of cigarette smoke on eIF2α phosphorylation Figure 9
Relative effect of vapor and particulate ('tar') phases of cigarette smoke on eIF2α phosphorylation. NHBE cells 
were exposed to air (mock treatment M), whole cigarette smoke (W), vapor phase (V) or particulate 'tar' phase (T) from 2R4F 
cigarettes, after which the cells were placed in fresh medium and returned to the incubator for the time periods specified. 
Vapor phase was created by passing whole smoke through a Cambridge pad filter to trap the particulate matter. Particulate 
'tar' phase was achieved by passing the whole smoke through 450 mg activated carbon to remove vapor phase components. 
Duration of whole smoke and vapor phase exposures was 20 minutes. Duration of particulate 'tar' phase exposures was 25 
minutes in order to deliver an amount of particulate matter equivalent to that of the whole smoke exposure as some particu-
late matter is lost upon transit through the activated carbon. In all exposures the 35 cc puffs were diluted in 250 cc air. West-
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Effect of antioxidant treatment on eIF2α phosphorylation following cigarette smoke exposure Figure 10
Effect of antioxidant treatment on eIF2α phosphorylation following cigarette smoke exposure. A549 cells were 
exposed to air (mock treatment) or 2R4F cigarette smoke for 20 minutes with 35 cc puffs diluted in 250 cc air, with or without 
concurrent treatment with NAC or GSH (at 5 and 25 mM concentrations), after which the cells were placed in fresh medium 
and returned to the incubator for the time periods specified. Western blots of whole cell lysates were probed with antibodies 
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and normal tissue controls (see Table 1). We assessed the
data in several ways. First, we determined if there were dif-
ferences in the expression of phospho-eIF2α, eIF2α, and
BiP between specimens of malignant and non-malignant
lung tissue specimens. Second, we determined if there
were differences in the expression of these three proteins
between the malignant and non-malignant cellular com-
partments of each individual lung cancer specimen. Third,
we determined if there was any meaningful correlation
between expression levels of these three proteins and any
clinicopathologic, demographic or smoking history
parameter. For all three proteins (i.e., phospho-eIF2α,
eIF2α, and BiP) we found that positive staining was
strictly limited to the cytoplasm of all tissues examined. In
addition, we did not observe any nuclear staining in any
normal or malignant tissue, or any staining with an irrel-
evant control antibody.
phospho-eIF2α
Representative immunohistochemical features of phos-
pho-eIF2α staining are shown in Figure 12. Table 2 sum-
marizes the immunoreactivity data and the statistical
analysis detailed in Table 3 indicates a significant differ-
ence (p  = 0.0025) between the mean phospho-eIF2α
immunohistochemical staining indices (ISIs) for the non-
small cell carcinoma diagnostic group and the normal
diagnostic group. Of the 93 assessable cases of NSCLCs,
52 (55.9%) showed a significant increase in expression of
phospho-eIF2α with an ISI between > 1–12 with many of
these showing intense staining. There were no statistically
significant differences in phospho-eIF2α expression
between the normal diagnostic group and either the small
cell lung carcinoma (SCLC) or mixed carcinoma (MC)
diagnostic groups. Table 4 compares the ISI levels in the
tumor compartment to the ISI levels in the normal com-
Contribution of vapor and particulate phases of CS to XBP1 splicing inhibition in A549 cells Figure 11
Contribution of vapor and particulate phases of CS to XBP1 splicing inhibition in A549 cells. A549 cells were 
exposed to air (mock treatment), whole cigarette smoke (CS), vapor phase, or particulate 'tar' phase from 2R4F cigarettes as 
described in the legend for Figure 6, then placed in fresh media with or without 1 uM thapsigargin (THAP) and incubated for 
the time periods specified. PCR was used to determine the relative amounts of spliced and unspliced XBP1. For each lane the 
extent of splicing was quantified as described in the Methods section and is presented in additional file 3 – Supplemental 
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partment for each of the carcinoma diagnostic groups. The
data indicate a statistically significant difference in expres-
sion of phospho-eIF2α between the malignant and non-
malignant cellular compartments of both the NSCLC (p =
< 0.0001) and MC (p = 0.0324) diagnostic groups, but not
the SCLC (p = 0.1833) diagnostic group.
eIF2α
Representative immunohistochemical features of eIF2α
staining are shown in Figure 12. Table 5 summarizes the
immunoreactivity data and the statistical analysis shown
in Table 6 indicates a significant difference between the
mean eIF2α ISIs for the NSCLC diagnostic group and the
normal diagnostic group (p = 0.0002), and between the
MC diagnostic group and the normal diagnostic group (p
= 0.0017). There was no statistically significant difference
between the mean eIF2α ISI for SCLC diagnostic group
and the normal diagnostic group (p = 0.5571). Of the 94
assessable cases of NSCLCs, 57 (60.6%) showed a consid-
erable increase in expression of eIF2α with an ISI between
> 1–12, although the intensity of protein expression was
considerably less than that seen for phospho-eIF2α. Seven
of eight assessable cases of MCs (87.5%) showed a statis-
tically significant increase in expression of eIF2α with an
ISI between > 1–12. Table 7 compares the ISI levels for
eIF2α in the tumor cell compartment to the ISI levels in
the normal cell compartment for each of the carcinoma
diagnostic groups. The data indicate a statistically signifi-
cant difference in expression of eIF2α between the malig-
nant and non-malignant cellular compartments in both
the NSCLC (p = < 0001) and MC (p = 0.0217) diagnostic
groups but not for the SCLC (p = 0.923) diagnostic group.
BiP
Representative immunohistochemical features of BiP
staining are shown in Figure 12. Table 8 summarizes the
immunoreactivity data and the statistical analysis shown
in Table 9 indicates a significant difference between the
mean BiP ISIs for the NSCLC diagnostic group and to the
normal diagnostic group (p = < 0.0001), and for the MC
diagnostic group and the normal diagnostic group (p = <
0.0001). There was no statistically significant difference
between the mean BiP ISIs for SCLC diagnostic group and
the normal diagnostic group (p  = 0.3299). Of the 95
assessable cases of NSCLCs, 83 (87.3%) showed a signifi-
cant increase in expression of BiP with an ISI between > 1–
12. Of the 8 assessable cases of MCs all 8 (100%) showed
a significant increase in expression of BiP with an ISI
between > 1–12 and, as observed for phospho-eIF2α,
many of these lung cancer cases displayed intense staining
patterns. Table 10 compares the ISI levels in the tumor cell
compartment to the ISI levels in the normal cell compart-
Table 2: Expression of phospho-eIF2α in normal and malignant lung specimens.
Immunohistochemical Staining Index (ISI)
Histology Cellular Compartment # of Cases 0–11 > 1–3 > 3–6 > 6–9 > 9–12
Normal Lung Tissue Normal cell compartment 8 8 0 0 0 0
Non-Small Cell Carcinoma2 93
Tumor cell compartment 41 18 22 9 3
Normal cell compartment 87 4 2 0 0
Small Cell Carcinoma2 4
Tumor cell compartment 2 0 1 1 0
Normal cell compartment 4 0 0 0 0
Mixed Carcinoma Types2 8
Tumor cell compartment 5 0 2 1 0
Normal cell compartment 8 0 0 0 0
1An ISI value of 0–1 is considered negative, while an ISI value of > 1 is considered positive, with the 4 groups (i.e., > 1–3, > 3–6, > 6–9, > 9–12) 
indicate an increasing level of expression intensity and rate.
2For each tissue specimen tumor cells and non-tumor cells were scored separately for percent immunohistochemical reactivity and staining 
intensity as described in the Methods Section. The product of the percentage and intensity scores was used to generate an immunohistochemical 
staining index (ISI) for each cellular component (i.e., tumor and non-tumor) of each specimen.
Table 3: phospho-eIF2α protein expression.
Diagnostic Group N Mean +/- SD P-value
Normal 8 0 --
Small Cell Carcinoma 4 3.00 ± 4.13 0.0875
Non-Small Cell Carcinoma 93 2.61 ± 2.77 0.0025*
Mixed Carcinoma 8 1.79 ± 2.39 0.0879
Mean immunostaining levels (± SD) and results of statistical testing for 
differences between the normal diagnostic group and each carcinoma 
type diagnostic group.
*Statistically significant (α = 0.05)BMC Cancer 2008, 8:229 http://www.biomedcentral.com/1471-2407/8/229
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ment for each carcinoma diagnostic group. The data indi-
cate a statistically significant difference in expression of
phospho-eIF2α between the malignant and non-malig-
nant cellular compartments in both the NSCLC (p = <
0.0001) and MC (p = < 0.0001) diagnostic groups but not
in the SCLC (p = 0.6116) diagnostic group.
Correlation with Clinicopathological Variables
Expression levels of eIF2α, phospho-eIF2α, and BiP in
tumor cells were assessed for any significant association
with a clinicopathologic, demographic, or smoking his-
tory parameter (i.e., age, gender, race, smoking history,
number of cigarettes/day, AJCC/UICC stage, and pT/pN
category). The only correlation found in these data was a
statistically significant increase in BiP in the NSCLC diag-
Table 4: phospho-eIF2α protein expression.
Cellular Compartment
Diagnostic Group N Normal Tumor P-value
Small Cell Carcinoma 4 0.21 ± 0.42 3.00 ± 4.13 0.1833
Non-Small Cell Carcinoma 90 0.24 ± 0.72 2.61 ± 2.77 < 0.0001*
Mixed Carcinoma 8 0.04 ± 0.12 1.79 ± 2.40 0.0324*
Mean immunostaining levels (± SD) and results of statistical testing for differences between the normal and tumor cell compartments for each 
diagnostic group.
*Statistically significant (α = 0.05)
Representative immunohistochemical expression features of phospho-eIF2α, eIF2α, and BiP proteins in different human lung  lesions Figure 12
Representative immunohistochemical expression features of phospho-eIF2α, eIF2α, and BiP proteins in differ-
ent human lung lesions. The proteins assessed by immunohistochemistry are designated in rows, while the columns depict 
expression in normal lung tissues, representative positive (ISI values of > 6–9) and negative NSCLCs, and representative posi-

























įBMC Cancer 2008, 8:229 http://www.biomedcentral.com/1471-2407/8/229
Page 21 of 30
(page number not for citation purposes)
nostic group with increasing age (p = 0.0187). Finally, we
assessed whether there was any concordance in expression
of eIF2α, phospho-eIF2α, and BiP in any tumor cell com-
partment. A Spearman rank correlation analysis [76] indi-
cated three statistically significant correlations for the
increased expression of: 1) phospho-eIF2α and eIF2α (p =
0.0071) in patients with NSCLCs; 2) eIF2α and BiP (p = <
0.0001) in patients with NSCLCs; and 3) phospho-eIF2α
and eIF2α (p = 0.0360) in patients of the MC diagnostic
group.
Discussion
The pyrolysis process in cigarettes generates a highly com-
plex mixture of reactive gases and suspended particulate
matter containing a wide range of carcinogens, tumor pro-
moters, toxins, and free radicals which cause direct and
indirect damage to the genome [77,78], transcriptome
[79,80], and proteome [81] of cells in the aerodigestive
tract of smokers on a daily basis [82,83]. This incessant
cycle of tissue injury and repair is presumed to be a major
contributor to the development of lung cancer [75,84-86].
However, a precise biological understanding of the nature
and temporal sequence of specific damaging events that
drive the formation and progression of this disease
remains elusive [87-91]. Compelling data support the
conclusion that one prominent form of CS-induced air-
way damage and a key etiological factor in lung cancer is
chronic oxidative stress and resulting inflammation [72-
75,84-86,92,93]. For example, 1) lung cancer is increased
in patients with chronic inflammation [84,94-96]; 2) pol-
ymorphisms and mutations in genes regulating the
inflammatory process are linked to lung cancer risk
[97,98]; 3) gene and proteomic studies of smoke-exposed
airway epithelium consistently shows the upregulation of
genes that respond to oxidants [30,31,99]; 4) the cycloox-
ygenase-2 (COX-2) isoenzyme, a key player in diverse
pro-inflammatory conditions, is frequently up-regulated
in lung neoplasms and correlates with a poor prognosis
[100,101]; 5) non-steroidal anti-inflammatory drugs
(e.g., selective COX-2 inhibitors such as Celecoxib) can
reduce the relative risk of lung cancer [102-105]; 6) CS can
depress levels of endogenous antioxidants such as glutath-
ione [74,106-108]; 7) synergy between pro-oxidant beta-
carotene cleavage products and resulting oxidative stress is
believed responsible for the increased rates of lung cancer
in long-term smokers enrolled in both the ATBC (Alpha-
Tocopherol Beta-Carotene) and CARET (beta-Carotene
and Retinol Efficacy) chemoprevention trials [109]; 8) a
mouse model system suggests that oxidative stress
induced in the lung by CS vapor phase components is a
key player in lung oncogenesis [85,110]; and 9) we have
previously shown that an early genomic defect caused by
the copious amounts of free radical generators in CS is the
induction of DNA double-strand DNA breaks (DSBs),
which are probable tumorigenic lesions in multiple can-
cers including those of the lung [111-113], and that free
radical scavenging antioxidants can prevent these DSBs
[3,5].
Table 5: Expression of eIF2α in normal and malignant lung specimens.
Immunohistochemical Staining Index (ISI)
Histology Cellular Compartment # of Cases 0–11 > 1–3 > 3–6 > 6–9 > 9–12
Normal Lung Tissue Normal cell compartment 8 2 6 0 0 0
Non-Small Cell Carcinoma2 94
Tumor cell compartment 37 41 14 1 1
Normal cell compartment 65 27 2 0 0
Small Cell Carcinoma2 5
Tumor cell compartment 4 1 0 0 0
Normal cell compartment 5 0 0 0 0
Mixed Carcinoma Types2 8
Tumor cell compartment 1 6 1 0 0
Normal cell compartment 7 1 0 0 0
1An ISI value of 0–1 is considered negative, while an ISI value of > 1 is considered positive, with the 4 groups (i.e., > 1–3, > 3–6, > 6–9, > 9–12) 
indicate an increasing level of expression intensity and rate.
2For each tissue specimen tumor cells and non-tumor cells were scored separately for percent immunohistochemical reactivity and staining 
intensity as described in the Methods Section. The product of the percentage and intensity scores was used to generate an immunohistochemical 
staining index (ISI) for each cellular component (i.e., tumor and non-tumor) of each specimen.
Table 6: eIF2α protein expression.
Diagnostic Group N Mean +/- SD P-value
Normal 8 0 --
Small Cell Carcinoma 5 0. 39 ± 0.67 0.5571
Non-Small Cell Carcinoma 94 1.62 ± 1.34 0.0002*
Mixed Carcinoma 8 1.73 ± 1.24 0.0017*
Mean immunostaining levels (± SD) and results of statistical testing for 
differences between the normal diagnostic group and each carcinoma 
type diagnostic group.
*Statistically significant (α = 0.05)BMC Cancer 2008, 8:229 http://www.biomedcentral.com/1471-2407/8/229
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Although a detailed understanding of the molecular
mechanisms that directly link oxidative stress, inflamma-
tion, and CS-induced pathologies is still lacking, a wealth
of data suggest that the large amounts of free radicals and
reactive species (such as ￿O2
-, ￿NO, ￿OH, etc) in the gas
phase, and more stable organic reactive species/oxidants
(such as phenols, hydroquinone, epoxides, etc.) in the
particulate phase of CS, overwhelm the respiratory tract's
steady-state antioxidant capacity causing a marked imbal-
ance in its redox status [114-116]. This persistent exoge-
nous source of oxidative stress is amplified and
augmented by an endogenous chronic host inflammatory
response at the sites of tissue damage that provides addi-
tional quantities of reactive oxygen and nitrogen com-
pounds (e.g., H2O2 and ￿NO), and reactive intermediates
such as peroxynitrite (ONOO- [86,117,118]. Combined,
these sources of reactive species can cause significant cel-
lular and tissue damage that the cell responds to in several
ways. One mechanism is to alter the expression of genes
that attenuate the effects of oxidative stress. For example,
as shown in additional file 1 – Supplemental Table S1:
Cigarette smoke signature genes, CS exposure induces
the expression of: a) thioredoxin reductase 1, a compo-
nent of a ubiquitous thiol oxidoreductase system that pro-
tects the cell from oxidative stress; b) heme oxygenase I
(HO-1), an enzyme that catabolizes heme containing pro-
teins with the subsequent production of free iron, CO,
and bilirubin; c) ferritin, which sequesters reactive iron
molecules and d) NAD(P)H:quinone acceptor oxidore-
ductase 1 (NQO1), a cytosolic flavoenzyme that catalyzes
reduction of quinones to hydroquinones and is part of the
oxidative stress response [119]. Each of these CS-respon-
sive genes is frequently upregulated in a range of cancers
including lung carcinomas [120-123]. Our data further
show that CS causes an increase in the expression of genes
pivotal to redox homeostasis as well as the synthesis of
glutathione: gamma glutamylcysteine ligase, catalytic and
modifier subunits. Chronic depletion in glutathione
related antioxidant enzymes by CS can lead to lung dam-
age and disease [124,125]. Since proteins are major targets
of oxidative damage, another predictable biological result
would be an accumulation of misfolded, aggregated, or
cross-linked proteins in the ER of the respiratory tract
which responds by activating a wide array of stress respon-
sive genes in order to restore homeostasis [126]. Support
for this hypothesis comes, in part, from the data presented
Table 7: eIF2α protein expression.
Cellular Compartment
Diagnostic Group N Normal Tumor P-value
Small Cell Carcinoma 5 0.28 ± 0.18 0.39 ± 0.67 0.923
Non-Small Cell Carcinoma 93 0.90 ± 0.72 1.62 ± 1.34 < 0.0001*
Mixed Carcinoma 8 0.81 ± 0.27 1.73 ± 1.24 0.0217*
Mean immunostaining levels (± SD) and results of statistical testing for differences between the normal and tumor cell compartments for each 
diagnostic group.
*Statistically significant (α = 0.05)
Table 8: Expression of BiP in normal and malignant lung specimens.
Immunohistochemical Staining Index (ISI)
Histology Cellular Compartment # of Cases 0–11 > 1–3 > 3–6 > 6–9 > 9–12
Normal Lung Tissue Normal cell compartment 8 6 2 0 0 0
Non-Small Cell Carcinoma2 95
Tumor cell compartment 12 30 26 19 8
Normal cell compartment 58 27 7 3 0
Small Cell Carcinoma2 5
Tumor cell compartment 4 0 0 1 0
Normal cell compartment 3 2 0 0 0
Mixed Carcinoma Types2 8
Tumor cell compartment 0 3 2 2 1
Normal cell compartment 7 1 0 0 0
1An ISI value of 0–1 is considered negative, while an ISI value of > 1 is considered positive, with the 4 groups (i.e., > 1–3, > 3–6, > 6–9, > 9–12) 
indicate an increasing level of expression intensity and rate.
2For each tissue specimen tumor cells and non-tumor cells were scored separately for percent immunohistochemical reactivity and staining 
intensity as described in the Methods Section. The product of the percentage and intensity scores was used to generate an immunohistochemical 
staining index (ISI) for each cellular component (i.e., tumor and non-tumor) of each specimen.BMC Cancer 2008, 8:229 http://www.biomedcentral.com/1471-2407/8/229
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in this study showing that CS causes ER stress and acti-
vates the UPR pathway via phosphorylation of eIF2α in a
PERK-dependent manner in human lung cells, which sup-
ports a similar conclusion reached in two recent papers
[30,31]
Our data further show that reactive radical species in both
whole smoke and the vapor phase are a dominant CS-
component causing ER stress [127]. A recent publication
by Hengstermann and Muller has concluded that the CS
gas phase component acrolein is a major inducer of ER
stress [31]. The ability of both GSH (the major intracellu-
lar antioxidant) and NAC, a synthetic acetylated form of
the amino acid L-cysteine and a thiol-containing antioxi-
dant, to scavenge CS-generated reactive oxygen species
(ROS) (e.g., ￿O2
-, H2O2, and ￿OH) [128,129] or sequester
reactive CS compounds that spawn free radicals intracel-
lularly (e.g., aldehydes, epoxides, quinones, etc.) further
supports the mechanistic relationship between CS-
induced reactive species and ER stress [130]. In these in
vitro experiments it is perhaps not surprising that the par-
ticulate phase of CS did not induce the UPR. This is pre-
sumably because many of the compounds that have
reactive potential in the particulate phase require either
enzymatic activation or generation via quinone/hydro-
quinone redox coupling in the presence of oxygen over
time [127,131]. Thus, the particulate phase does not result
in a bolus of free radicals at short time periods but rather
chronic low-level radical generation over extended time
periods [131,132]. Vapor phase components are inher-
ently smaller/more reactive than particulate phase com-
ponents and therefore have a higher likelihood of reacting
with biological components immediately upon exposure
as well as crossing phospholipid membranes more
quickly than larger molecules. Consequently, it is proba-
ble that since we exposed cells to CS for only 15–20 min-
utes, there is insufficient time for reactive species to form
within the cell and induce the UPR pathway. Presumably,
this is not the case in vivo where chronic cigarette smok-
ing would provide sufficient time for the reactive species
in the particulate phase to impact protein structures and
induce molecular circuits like the UPR.
Another interesting observation to emerge from this study
is that CS significantly suppressed the splicing of the XBP1
mRNA to its active truncated form. The ability of CS to
modulate the expression of XBP1, if mirrored in vivo in
smokers, may have significant ramifications for the devel-
opment and progression of lung neoplasms since XBP1
not only has a primary role in maintaining ER homeosta-
sis [22,133], but also important regulatory functions in
DNA damage and repair pathways, redox homeostasis
and oxidative stress responses [22]. Thus, impairment of
this key effector arm of the UPR pathway could have con-
siderable detrimental short and long-term effects in smok-
ers. The mechanism by which CS suppresses XBP1
splicing is not obvious. It is possible that one or more
components of CS can attack the structure of the IRE1
transmembrane protein thereby disabling its ribonuclease
function and subsequent splicing of the XBP1 mRNA to its
transcriptionally active isoform. Another possibility is
that CS activates a protein that inhibits elements of the
ER-stress induced UPR pathway. For example, the Bax
inhibitor-1 (BI-1) protein has been shown to suppress
apoptosis [134], ER-stress related protein expression, and
XBP1 splicing [135]. Moreover, it has been shown that,
depending upon the subtype, some 43% to 82% of lung
adenocarcinomas overexpress BI-1 [136]. Eliminating or
down-regulating proapoptotic signals are a major step in
the evolution of most, if not all, human malignancies. We
are currently assessing if CS suppresses XBP1 splicing by
inducing or augmenting BI-1 expression in lung cells. A
recent paper has presented evidence showing that mouse
Table 9: BiP protein expression.
Diagnostic Group N Mean ± SD P-value
Normal 8 0 --
Small Cell Carcinoma 5 1.37 ± 3.06 0.3299
Non-Small Cell Carcinoma 95 4.39 ± 2.92 < 0.0001*
Mixed Carcinoma 8 5.27 ± 3.20 < 0.0001*
Mean immunostaining levels (± SD) and results of statistical testing for 
differences between the normal diagnostic group and each carcinoma 
type diagnostic group.
*Statistically significant (α = 0.05)
Table 10: BiP protein expression.
Cellular Compartment
Diagnostic Group N Normal Tumor P-Value
Small Cell Carcinoma 5 0.90 ± 0.50 1.37 ± 3.06 0.6116
Non-Small Cell Carcinoma 95 1.26 ± 1.48 4.39 ± 2.92 < 0.0001*
Mixed Carcinoma 9 0.37 ± 0.51 5.27 ± 3.20 < 0.0001*
Mean immunostaining levels (± SD) and results of statistical testing for differences between the normal and tumor cell compartments for each 
diagnostic group.
*Statistically significant (α = 0.05)BMC Cancer 2008, 8:229 http://www.biomedcentral.com/1471-2407/8/229
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3T3 cells exposed to aqueous extracts of CS displayed only
minute amounts of spliced XBP1 mRNA [31]. The conclu-
sion of this paper was that CS did not activate the IRE1
sensor and therefore resulted in negligible XBP1 splicing.
In contrast, we provide evidence that CS actively sup-
presses the splicing of XBP1. If this phenomenon occurs
in vivo in smokers, it could have physiological relevance
in terms of altering the balance between cell survival and
cell death. Lin et al have recently shown that IRE1 and
ATF6 activities were attenuated by persistent ER stress in
human cells resulting in increased cell death [61]. Clearly,
further research to determine if IRE1 activation and/or
XBP1 splicing is corrupted in actual smokers would be val-
uable. Finally, we showed that the third effector arm of the
UPR signaling pathway, ATF6, is also activated by CS as
evidenced by cleavage of the ATF6 protein and the appear-
ance of downstream transcriptional targets of ATF6 such
as XBP1 and BiP.
If activation of the UPR program occurs in smokers on a
daily basis due to oxidative stress, it could evolve into a
long-term problem either because of persistent damage
directly related to its activation, or because as a functional
barrier to transformation and tumor progression, it pro-
vides an attractive target for disablement. Either scenario
would allow the respiratory cell to sustain additional
damage to mechanisms that maintain lung homeostasis
which could eventually lead to neoplastic transformation
[137,138]. A number of studies have suggested that habit-
ual activation of UPR plays a major role in etiology of can-
cer as well as many other diseases [35,36,139,140]. Tumor
cells are subjected to considerable internal stress due to
genetic instability, hypoxia, signaling distortion, immune
attack, and disorganized cross-talk with the surrounding
normal microenvironment [141]. Many of these stressful
situations can cause ER dysfunction from which the cell
must defend itself. Consequently, a prevailing hypothesis
is that upregulation of UPR components in malignant
cells provides an anti-apoptotic, pro-survival advantage
by increasing resistance to ER stress induced by endog-
enous sources (e.g., hypoxia, genetic instability, etc.)
[10,36,64,142] or exogenous sources (such as chemother-
apeutic drugs) [32,143]. Evidence to support this idea
comes from numerous studies showing the increased
expression of one or more UPR-relevant proteins in mul-
tiple tumors including those of the breast (i.e., BiP [144]),
liver (ATF6, XBP1 and BiP [145]), stomach (BiP [146]),
brain (BiP [143]), esophagus (Grp94 [147]), and lung
(BiP and Grp94 [148,149]). Our analysis of lung cancer
tissue specimens is also consistent with this hypothesis.
For example, we found that compared to non-malignant
lung tissue, there is a significant increase in expression of
phospho-eIF2α in a majority of cases of NSCLCs (55.9%;
p = 0.0025) but not in either SCLCs or MCs. We further
found a significant increase in expression of BiP in a
majority of cases of NSCLCs (87.5%; p = < 0.0001) and
MCs (100%; p = < 0.0001), but not in SCLCs. The eIF2α
protein was also overexpressed in a majority of cases of
both NSCLCs (60.6%; p = 0.0002) and MCs (87.5%; p =
0.0017), but not in SCLCs. Rosenwald et al. have previ-
ously shown that eIF2α is frequently increased in bronchi-
oloalveolar carcinomas (BAs) but only rarely in squamous
cell carcinomas (SCCs) [150]. Since both BAs and SCCs
are subgroups of NSCLCs that share the histological fea-
ture of being derived from lung epithelium [151], these
data differ somewhat from ours which showed a statisti-
cally significant increase in eIF2α expression in the tumor
cell compartments of SCCs as well as in the other major
NSCLC histological subtypes (i.e., adenocarcinoma, ade-
nosquamous carcinoma, and large cell carcinoma) for
which we had a sufficient number of cases. Resolution of
the differences between our results and that of Rosenwald
et al. awaits further research. However, an important
caveat to our data is that the small number of SCLC cases
available for assessment (i.e., 5) could potentially obscure
any reliable protein expression differences.
Although our data support the conclusion that modula-
tors of the UPR pathway are chronically impacted in this
tumor type, aside from a modestly significant increase in
BiP in the NSCLC diagnostic group with increasing age (p
= 0.0187), we found no obvious correlation with any his-
topathological criteria such as gender, pathologic stage,
histological type, or TMN-status and the increased expres-
sion of eIF2α, phospho-eIF2α, and BiP. Uramoto et al.
[149] similarly found no significant difference between
BiP expression and any clinicopathological parameter. A
recent lung cancer study by Wang et al. [148], though
finding no correlation of increased expression of BiP with
pathologic tumor type, did relate augmented expression
in less differentiated tumors and in more advanced stage
III tumors, both aspects predicting a poorer prognosis.
However, Uramoto et al. [149] found increased expres-
sion of BiP in a majority of lung cancers but these patients
had a better prognosis than those with BiP-negative can-
cers. In our current study, we could not determine the rela-
tionship between expression and prognosis due to a lack
of detailed clinical outcome data on the patients from
whom the tumor specimens we assessed originated.
Paradoxically, although our study showed that increased
expression of eIF2α, phospho-eIF2α, and BiP are patho-
genic features of lung cancers, none of these proteins iden-
tified lung cancers as having arisen in a smoker or
nonsmoker. Does this mean that the induced expression
of these UPR-related proteins is not directly related to CS
exposure or, alternatively, that their induction is a general
convergent feature of lung cancers regardless of the pro-
voking stimulus? Since oxidative stress resulting from pas-
sive cigarette smoking is certainly one etiological factor inBMC Cancer 2008, 8:229 http://www.biomedcentral.com/1471-2407/8/229
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the development of lung cancers in nonsmokers
[75,84,85,92,152,153] the latter interpretation is more
likely. It is also possible that the UPR is induced in CS-
exposed lung cells prior to malignancy but also subse-
quent to the development of a cancer that has regions of
hypoxia. For example, it is well documented that hypoxia
is present in a majority of human solid tumors, including
lung cancers, and that hypoxic regions can have selective
resistance to various therapeutic modalities [53,154].
Thus, one prosurvival mechanism of hypoxic tumor cells
is to diminish protein translation and energy utilization,
which can occur as a direct result of activation of the UPR
pathway. Accordingly, induction of UPR via eIF2α phos-
phorylation is required for hypoxic cell survival and
tumor growth [53]. In addition, hypoxia can also induce
the expression of BiP [155]. Thus, it remains to be deter-
mined if the expression of peIF2α and BiP that we
observed in a majority of human lung cancers occurs rela-
tively late in their evolution as the result of hypoxic con-
ditions, or reflects an early activated prosurvival
mechanism in asymptomatic lung cells undergoing
chronic ER stress due to CS or some other environmental
contaminant. While our data to date do not strongly sup-
port either possibility, a recent study using a proteomic
approach showed that lung samples from chronic smok-
ers demonstrated a number of differentially expressed
proteins compared to nonsmokers [30]. For example, sev-
eral UPR proteins, including BiP and calreticulin, were
found to be up-regulated in smokers. The conclusion of
these data was that activation of UPR by CS may protect
the lung from oxidant injury and the development of
chronic obstructive pulmonary disease, a strong risk factor
for the development of lung cancer.
In summary, while more studies are needed to clarify how
chronic activation, expression, or dysregulation of key
UPR-regulated proteins impact the trajectory of CS-
induced lung disease, it seems highly likely that the UPR
pathway is a one of several molecular mechanisms pro-
moting tumor cell evolution that could be attenuated or
reversed resulting in a more efficacious treatment strategy
for lung cancers [87-90,156-158]. Targeting one or more
UPR effectors, either unilaterally or in combination with
conventional cytotoxic drugs, may be a particularly
important treatment opportunity since the current stand-
ard of care for patients with advanced lung cancer remains
disappointing [33,35,36,137,156]. Direct support for this
proposition has recently come from a study showing that
bortezomib (PS-341, Velcade™), a potent proteasome
inhibitor currently approved for the treatment of multiple
myeloma, sensitizes pancreatic cancer cells to ER stress-
induced apoptosis and strongly enhances the anticancer
activity of cisplatin [159].
Conclusion
The following conclusions can be drawn from these data.
First, since different types of cigarettes are equally effective
at inducing ER stress and activating the UPR pathway, it
suggests that the toxicity and chemical composition of CS
is relatively constant across different brands of cigarettes,
an observation consistent with epidemiological and expo-
sure studies that find no essential difference in lung cancer
risk among long-term smokers of different cigarette types
(i.e., ultralight, light, or full-flavor)[44,46], and no signif-
icant quantitative differences in markers of carcinogen
and nicotine uptake among these smokers [46,160]. Sec-
ond, the induction of ER stress in combination with
chronic activation of multiple effectors of the UPR path-
way by CS may play a pivotal role in the etiology and/or
progression of lung cancers and other pulmonary dis-
eases. And third, perturbations in phospho-eIF2α, as well
as BiP and eIF2α, may have diagnostic and/or therapeutic
potential in the clinical management of patients with var-
ious lung malignancies.
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